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Abstract
Background: Medical research studies are becoming increasingly important for optimizing the prevention,
diagnosis and treatment of illnesses. Participation in research studies can have many benefits for patients. In
randomized and controlled clinical studies, they can receive the best possible medical care currently available.
However, only a small proportion of patients nowadays are treated within the framework of medical research. The
primary endpoint of this study was to discover what level of knowledge patients have about clinical studies and
how they currently perceive them, in order to identify ways of optimizing the information provided about studies
from the patients’ point of view.
Methods: The study included 2546 patients (breast cancer 21.6 %, gynecological cancer 8.3 %, obstetrics 32.7 %,
endometriosis 7.8 %, fertility treatment 3.2 %, other benign gynecological illnesses 19.2 %, no information for 7.2 %)
in the outpatient clinic (45.2 %) and in the in-patient sector (54.8 %) at the Department of Gynecology at Erlangen
University Hospital and associated centers. In the single-center study, conducted between January 2011 and
January 2012, the patients were asked about their level of knowledge regarding the background to medical
research studies and the ways in which they are carried out and used. The patients were also asked how they
perceived medical studies and how they thought study conditions might be optimized. The three-page
questionnaire was included in the feedback sheet received by patients as part of the hospital’s quality management
system.
Results: As a whole, the group only had moderate knowledge about clinical studies. A majority of the respondents
considered that studies were valuable (91.6 %), but only a few were also willing to take part in them (58.4 %).
Knowledge and willingness to participate strongly depended on age (P < 0.001), educational level (P < 0.001) and
patient group (P < 0.001). Most patients would prefer to decide about participating in studies through a discussion
with their outpatient physicians.
Conclusions: The information that patients have about clinical studies affects whether they participate in them. It is
therefore extremely important for patients to be well informed, for their anxieties about participation to be relieved,
and for the benefits of participation to be explained to them.
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Background
Medical research studies are today the gold standard
for the development of new types of medical proced-
ure, treatments, drugs, etc. They help to transfer the
latest scientific discoveries to clinical practice. They
therefore have great potential benefits for patients who
participate in them, and thanks to strict standards and
regulations they have very high safety requirements.
Treatment in the context of a clinical study is claimed
to be equivalent to or better than the standard treat-
ment and implies increasingly new therapeutic options,
particularly in the field of oncology [1]. In addition, the
results of further studies suggest that patients treated
in research studies have an improved quality of life [2].
Care for participants in a clinical study is much more
intensive, and more information is provided to the pa-
tient about the causes and management of disease; this
leads to an additional positive psychological effect [3].
Despite this, however, participation rates in clinical
studies are extremely low [4].
To increase the numbers of patients participating in
research studies, both an optimal study design and also
adequate provision of information are extremely import-
ant. It is therefore of decisive importance to know from
the patients’ point of view what level of knowledge they
have about clinical studies and how they currently per-
ceive them, and to know about ways they think the in-
formation provided could be optimized.
The present study investigated the general level of
knowledge on the topic of “clinical studies” in a group of
patients being treated at a university gynecology depart-
ment. In addition, the way in which they perceived the
design and conduct of studies and their attitudes to
them were also noted.
Methods
Between January 2011 and January 2012, outpatients and
in-patients at the Department of Gynecology at Erlangen
University Hospital were asked to complete a question-
naire to assess the level of knowledge they had about
clinical studies and how they perceived them, as the pri-
mary endpoint. The secondary endpoint was the analysis
of differences between the subgroups with different
diseases.
The questionnaire included 25 questions and was
linked to the survey about patient satisfaction, given to
all patients in the department as part of quality manage-
ment. The questionnaire was filled out at the end of the
outpatient visit or in-patient stay, to avoid stress for pa-
tients who might be waiting for a diagnostic or thera-
peutic procedure.
The first section of the questionnaire covered their
knowledge relative to nine statements about clinical
studies; the patients had to assess the truth of these
statements. The second section consisted of 13 closed
questions, each with the optional answers “yes/don’t
know/no.” The questionnaire also included three open
questions on the topic of the value of clinical studies
and factors potentially influencing participation in them.
In addition to these data, the condition being treated,
the patient’s highest educational level, and age and time
since first diagnosis were also recorded. After the ques-
tionnaire had been distributed for 4 weeks initially, the
pattern with which patients completed the questionnaire
and its comprehensibility were checked. During this val-
idation phase, no evidence was found that the question-
naire was difficult to understand.
The study was approved by the Ethics Committee of
the University of Erlangen.
In addition to direct analysis of the responses to the
nine individual statements, four of the statements were
prospectively selected as being clearly correctly answer-
able, and the numbers of correct answers from each pa-
tient were added up to a create a score (0–4). The score
was used as a separate indicator of the patients’ know-
ledge about clinical studies, comparable to the know-
ledge scale developed by Ellis and colleagues [5]: “Do
you know what the word ‘randomization’ means?” (an-
swer: “yes”); “Clinical studies make it possible to find out
whether the standard treatment or a new method is
more effective” (answer: “yes”); “Research studies cannot
be used in the treatment of severe diseases” (answer:
“no”); and “After you agree to take part in a study, with-
drawing from it later on is no longer possible” (answer:
“no”). The classification of the results distinguished be-
tween “insufficiently informed” (zero or one correct an-
swer), “moderately well informed” (two or three correct
answers) and “well informed” (four correct answers).
Percentages were always calculated relative to the num-
ber of patients who responded to each statement or an-
swered each question.
IBM SPSS Statistics for Windows, version 20.0
(Armonk, NY: IBM Corporation) was used for the statis-
tical analysis. The data were analyzed in relation to gen-
eral frequency distributions. In view of the size of the
group of patients, a chi-squared distribution of the test
variables was assumed in order to check independence.
Evidence of independence was assessed using a chi-
squared test. The α significance level was set at 0.05.
Results
Between January 2011 and January 2012, 2546 patients
completed the questionnaire (Table 1). Among 2363 pa-
tients for whom information about their presenting con-
dition was available, 211 (8.9 %) had presented due to a
gynecological cancer; 550 (23.3 %) due to breast cancer;
832 (35.2 %) due to pregnancy or birth; 82 (3.5 %) for
fertility treatment; 198 (8.4 %) due to endometriosis; and
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490 (20.7 %) due to a benign gynecological disease. The
patients’ mean age was 42.1 years (range 14–96 years).
With regard to the patients’ level of knowledge
about clinical studies, the responses to the nine
questions in the first section of the questionnaire are
presented in Table 2. The individual questions were
answered by the patients with different frequencies
(range n = 1914–1971). Statistical analyses did not
identify any subgroups that had answered all of the
questions or omitted to answer all of the questions in
any section. The four clearly true or false statements
were analyzed using a score (the sum of correct an-
swers given by each patient) as an indicator of existing
knowledge about clinical studies (Fig. 1). The score
was calculated from a total of 2005 patients. On aver-
age, the patients assessed 2.06 statements correctly;
233 patients (11.6 %) had all four answers right, 543
(27.0 %) had three answers correct, 558 (27.8 %) had
two answers right, 464 (23.1 %) had one answer right,
and 208 (10.4 %) had no correct answers. Patients who
presented in the department due to pregnancy or birth
had an average of 2.3 answers right; patients with
gynecological diseases had 1.79; patients with breast
cancer had 1.97; patients attending for fertility treat-
ment had 2.11; patients with endometriosis had 1.9;
and patients with benign gynecological diseases had
2.04 (P < 0.001) (Fig. 2). The level of education showed
a significant effect on the results in the knowledge
scale (P < 0.001). A higher educational level was asso-
ciated with more correct answers (Table 3). With re-
gard to the analysis of age, the overall group was
divided into nine age groups. The results for the key
questions showed significant differences relative to age
(P < 0.001). Participants aged 31–40 years responded
to most questions correctly. The mean for correct
statements decreased with increasing age (Table 4).
In the overall group (n = 1985), 91.6 % of the patients
regarded research studies as useful (Table 5). However,
only 52.8 % of the patients (n = 1992) stated that they
would consider taking part in studies themselves
(Table 5). Research studies were regarded as more use-
ful with increasing educational level: 82.6 % (n = 19)
without educational qualifications and 85.0 % (n = 250)
with a high-school certificate, versus 96.5 % (n = 475)
with a university degree (P < 0.001). This significant in-
fluence was also observed in relation to the question of
whether patients would consider taking part in studies
themselves: 26.1 % (n = 6) without qualifications and
43.8 % (n = 130) with a high-school certificate, versus
59.9 % (n = 299) with a university degree (P < 0.001). In
the different age groups, participants aged 31–40 years
included the highest proportion who regarded clinical
studies as useful: 95.2 % (n = 491) thought studies were
beneficial. Very young and older patients had a less
positive view: 71.4 % (n = 15) of patients < 21 years,
88.7 % (n = 47) of patients aged 71–80 years, and
71.4 % (n = 5) of patients aged 81–90 years (P = 0.001).
These views were also reflected in the patients’ actual
Table 1 Characteristics of the patients
Characteristics n %
Overall group 2546 100.0
Age Mean 42.1 y (range 14–96 y)
Information 1758 100.0
<21 y 29 1.6
21–30 y 332 18.9
31–40 y 601 34.2
41–50 y 350 19.9
51–60 y 229 13.0
61–70 y 142 8.1
71–80 y 63 3.6
81–90 y 10 0.6
>90 y 2 0.1
No information 788 –
Presenting condition Information 2363 100.0
Pregnancy/birth 832 35.2
Gynecological cancer 211 8.9
Breast disease 550 23.3
Fertility treatment 82 3.5
Endometriosis 198 8.4
Benign gynecological disease 490 20.7
No information 183 –
Educational level Information 1929 100.0
No graduation 23 1.2
High school 307 15.9
Secondary school 694 36.0
Higher education 300 15.6
University 510 26.4
Doctoral degree 90 4.7
Postdoctoral degree 5 0.3
No information 617 –
Postdiagnosis period Mean 2.0 y (range 1–7 y)
Information 689 100.0
0–1 y 351 50.9
1–2 y 209 30.3
2–3 y 34 4.9
3–4 y 25 3.6
4–5 y 17 2.5
5–6 y 51 7.4
6–7 y 2 0.3
No information 1857 –
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willingness to participate in a trial: 59.3 % (n = 169) of
those aged 41–50 years and 61.6 % (n = 109) of those
aged 51–60 years were willing to participate, while only
44.6 % (n = 120) of those aged 21–30 years and 42.9 %
(n = 3) of women aged 81–90 years would consider par-
ticipation (P = 0.001).
Among patients who were willing to participate,
15.9 % would be willing to take part in drug tests,
75.2 % in surveys, 54.7 % in tests of new treatment
methods, and 32.5 % in studies on ways of improv-
ing diagnosis (n = 1351). Patients with breast cancer
(n = 271) were most likely to take part in a study
(64.4 %), followed by 55.0 % of patients with endo-
metriosis (n = 160), 52.7 % of those with a gynecological
cancer (n = 165), 49.6 % of those with a benign
gynecological disease (n = 379), 48.6 % of those attending
for pregnancy or birth (n = 716), and 48.4 % of those re-
ceiving fertility treatment (n = 64) (P = 0.001).
Table 2 Summary of statements to assess patients’ level of knowledge about the design and conduct of studies (questions on the
rating scale are marked in bold type)
Statement Yes % (n) Don’t know % (n) No % (n) Total
Research studies are used when traditional medicine has failed. 18.5 (365) 28.2 (555) 53.3 (1051) 1971
Taking part in research studies involves greater risks for patients than
standard therapy.
17.1 (336) 85.9 (685) 48.0 (943) 1964
The quality of treatment in research studies is much better. 21.9 (429) 54.9 (1074) 23.2 (453) 1956
In a clinical study, the physician treating you will ensure that you receive
the treatment that is the best possible for you.
47.8 (914) 37.9 (726) 14.3 (274) 1914
Do you know what the word “randomization” means? 20.1 (396) – 79.9 (1573) 1969
Clinical studies make it possible to find out whether the standard
treatment or a new method is more effective.
83.7 (1640) 14.7 (288) 1.6 (32) 1960
Research studies cannot be used in the treatment of severe diseases. 8.4 (164) 43.1 (839) 48.5 (945) 1948
Clinical studies test the effects of procedures, drugs, or treatments that no
one is yet certain about.
51.5 (1004) 23.9 (466) 24.6 (480) 1950
After you agree to take part in a study, withdrawing from it later on
is no longer possible.
4.4 (85) 35.9 (699) 59.7 (1161) 1945
Fig. 1 Analysis of patients’ knowledge about clinical studies (relative frequencies of numbers of correct answers)
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Only 11.6 % of the patients (n = 1918) would be influ-
enced in favor of taking part in research studies if they were
to receive financial remuneration for it (Table 5). Patients
receiving fertility treatment were most likely, at 21.9 %, to
be positively influenced by financial remuneration (n = 64),
while patientswith breast disease (n = 412) and gynecological
cancers (n = 154) were least likely, at 4.1 % and 8.4 %, respect-
ively (P = 0.001).Educational leveldidnothavea significantef-
fect on willingness to participate relative to financial
remuneration (P = 0.265). Financial remuneration showed a
linear correlation with age: 17 % (n = 44) of women aged
21–30 years and 14.0 % (n = 71) of those aged 31–40 years
stated that it would have a positive influence on their par-
ticipation. This proportion decreased with increasing age,
down to 2.1 % of patients aged 71–80 years and none of
those who were older (P < 0.001).
A total of 494 of 1919 patients (25.7 %) would prefer
to make any decisions about study participation alone;
1121 (58.4 %) would prefer to make the decision them-
selves after careful consultation with the physician treat-
ing them, while 279 patients (14.5 %) would make the
decision jointly with their physician. Twenty patients
(1.0 %) would allow the physician to make the decision
about study participation after the patient had been
asked for her own opinion. Five patients (0.3 %) wanted
the physician alone to make the decision.
The preferred method of obtaining information about
a study was through a specialist physician, in 81.3 % of
the patients, followed by receiving information from the
family physician in 5.9 % (n = 1383). Among patients
with high-school certificates, 75.5 % (n = 142) wished to
obtain information about a study from a specialist and
Fig. 2 Means for the sum of correct answers from each patient relative to the patients’ presenting conditions
Table 3 Results from the knowledge rating scale relative to educational level
Highest educational level n Mean Standard deviation Median P
No qualifications 23 1.48 1.201 1 <0.001
High-school certificate 299 1.34 1.011 1
Secondary school 671 1.87 1.044 2
Higher education 294 2.13 1.063 2
University 498 2.57 1.081 3
Doctoral degree 88 3.38 1.043 4
Postdoctoral degree 5 3.20 1.304 4
Total 1878 2.11 1.170 2
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8 % (n = 15) from the family physician. In those with uni-
versity degrees, 84.6 % (n = 55) preferred specialists and
only 3.1 % (n = 2) preferred their family doctor (P = 0.021).
Age did not have a significant influence (P = 0.191).
When receiving information about the nature of a study
in which they might participate, 1763 of 1838 patients
(95.9 %) wanted to receive all available information about
the study, while only 63 (3.4 %) in principle wanted only as
little information about the study as possible. The wish to
receive the maximum information about a study increased
significantly with a higher level of education — high-school
certificate 91.8 % (n = 247) versus university degree 97.9 %
(n = 466; P = 0.006) — and decreased continuously with
increasing age: 97.2 % (n = 240) of patients aged 21–30
years versus 87.0 % (n = 40) of those aged 71–80 years
(P < 0.001).
A total of 1283 patients (37.1 %) thought that future
generations would benefit most from their participation
in the study; 929 (26.9 %) thought that they themselves
would benefit most as patients; 459 (13.3 %) thought the
physician would benefit most; 431 (12.5 %) thought the
pharmaceutical industry would benefit most; 259 (7.5 %)
thought hospitals would benefit most; and 94 (2.7 %)
thought that the health insurance company would bene-
fit most (multiple answers were possible).
Only 2.6 % of all patients (n = 1926) feared that de-
clining to participate in a study would have negative ef-
fects on the way in which they were treated, and only
2.0 % of all patients (n = 1926) feared negative effects
on their relationship with the physician treating them
(Table 5). Educational level did not have a significant
influence on the patients’ view that a negative relation-
ship with the treating physician might develop if they
declined study participation (P = 0.762); 4.8 % (n = 14)
of patients with high-school certificates were afraid that
there might be a negative effect on treatment, while
only 1.4 % (n = 7) of the patients with university degrees
feared this (P < 0.001). Anxiety regarding a negative in-
fluence on their treatment if they declined to partici-
pate was expressed more frequently by younger
patients: 2.0 % (n = 10) of those aged 31–40 years ver-
sus 0 % of all patients > 70 years (P = 0.001). Similar re-
sults were observed for the patients’ relationship with
the physician (2.4 % versus 0 %; P = 0.002).
In all, 29.1 % of the patients (n = 1881) wanted to re-
ceive more information about available clinical studies
(Table 5). More information about available studies was
wanted particularly (46.2 %) by patients receiving fertil-
ity treatment (n = 65), followed by 37.2 % of patients
with breast cancer (n = 409), 36.1 % of patients with
endometriosis (n = 147), and 30.8 % of patients with a
gynecological cancer (P = 0.001). Educational level did
not have a significant effect on patients’ desire to re-
ceive further information about available clinical trials
(P = 0.189). Patients aged 51–60 years had the strongest
desire to receive further information about available
studies (41.1 %, n = 72). This decreased continuously in
Table 4 Results from the knowledge rating scale relative to age
Age group n Mean Standard deviation Median P
<21 years 21 1.43 1.287 1 <0.001
21-30 years 268 2.05 1.107 2
31–40 years 520 2.36 1.133 2
41–50 years 283 2.11 1.203 2
51–60 years 183 1.98 1.160 2
61–70 years 110 1.85 1.060 2
71–80 years 52 1.33 0.985 1
81–90 years 7 1.00 1.000 1
>90 years 1 0.00 – 0
Total 1445 2.11 1.164 2
Table 5 Summary of opinions in the group regarding the value of clinical studies and factors potentially influencing participation
Question Yes % (n) Don’t know % (n) No % (n) Total
Do you think research studies are useful? 91.6 (1819) 7.8 (155) 0.6 (11) 1985
Would you be willing to take part in research studies? 52.8 (1052) 30.5 (608) 16.7 (332) 1992
Would a recommendation to take part in research studies by public
institutions such as German Cancer Aid or the German Cancer Society
influence your willingness to take part?
33.4 (634) 32.7 (622) 33.9 (645) 1901
Would financial compensation influence your willingness to take part? 11.6 (223) 24.1 (462) 64.3 (1233) 1918
Do you think that declining to take part in research studies could have
negative effects on the treatment you receive?
2.6 (50) 23.8 (458) 73.6 (1418) 1926
Do you think that declining to take part in research studies could have
negative effects on your relationship with the physician treating you?
2.0 (38) 22.9 (441) 75.1 (1447) 1926
Would you like to receive more information about clinical studies that
are available?
29.1 (548) 17.5 (330) 53.3 (1003) 1881
Is the availability of research studies at our hospital one reason why you
came here for treatment?
7.8 (149) 5.1 (98) 87.1 (1673) 1920
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lower and higher age groups: 24.3 % (n = 63) of patients
aged 21–30 years and 31.1 % (n = 14) of women aged
71–80 (P = 0.011).
Only 7.8 % of the patients (n = 1920) presented at the
Department of Gynecology at Erlangen University Hospital
specifically because of the availability of research studies
(Table 5).
Discussion
It has been shown in a wide variety of studies that
treatment in the framework of research studies has ad-
vantages for patients — partly because more intensive
clinical care and monitoring is provided, and also be-
cause there are positive psychological effects involving
better coping with the disease and the ability to receive
the latest innovative therapies [3]. In addition, research
studies lead to increased knowledge about the patho-
genesis and risk factors in diseases [6]. In a question-
naire study conducted among American oncologists by
Somkin et al. in 2005, 67 % of the physicians stated that
the treatment of patients in clinical studies was always
the treatment of choice [7]. Despite this, recruitment
rates of research studies are well below 10 % in many
certified centers [8]. The study recruitment rate for all
certified German breast cancer centers in 2012 showed
a median of 11.3 % [9]. It is therefore clearly necessary
to optimize recruitment strategies. These strategies
should be based on the patients’ attitudes and know-
ledge about clinical studies.
The present study shows that patients are on average
“moderately well-informed” in relation to clinical stud-
ies, according to a score based on four questions used as
a separate indicator of existing knowledge about clinical
studies — i.e., the patients answered an average of 2.06
questions correctly. Middle-aged patients, those with a
high educational level, and those presenting with preg-
nancy or endometriosis had the best levels of informa-
tion about studies.
A report from Australia calculated a knowledge score
on the topic of clinical studies among 50 outpatient in-
ternal medicine/oncology patients [5]. The findings
showed that 51.0 % of the patients agreed with the
statement that a clinical study discovers whether one
method works better than another. A systematic review
and meta-analysis included 103 studies analyzing pa-
tients’ knowledge about different aspects of clinical tri-
als. The pooled percentage of participants was 62.9 %
for knowing that treatments were being compared [10].
In comparison, 83.7 % of the patients in the present
study agreed that this statement was true. By contrast,
74.0 % of the Australian group were certain that the
physician treating them would ensure that a patient
taking part in a study would receive the best possible
treatment — whereas in the present study only 47.8 %
agreed with this. There was a correspondence in rela-
tion to the statement that clinical studies are only used
when the situation is hopeless (18.0 % versus 18.5 %).
The view that clinical studies test procedures etc. that
no one is yet certain about was agreed to by only
19.0 % in the Australian group, in comparison with
51.5 % of the patients in the present study. Evidently,
patients in the present group were much more uncer-
tain in relation to the individual questions listed. Both
questionnaires used the knowledge rating scale tool.
Studies have identified a positive connection between
patients’ willingness to participate and the number of
correct answers regarding knowledge about clinical
studies [8, 11]. By comparison, the median score in the
present group was two (out of four key questions), with
the average lying at 51.5 %, while in Australia it was
three out of seven questions. The meta-analysis showed
that the proportion of participants who understood dif-
ferent components of clinical trials varied from 52.1 %
to 75.8 % [10].
Bergenmar and colleagues have factors associated with
patients’ knowledge and perceived understanding of clin-
ical trials by using a knowledge score test in 268 patients
who consented to participate in a clinical trial [12]. No
significant associations were found between knowledge
and clinical and socio-economic factors. In contrast to
these findings, the present study shows significant influ-
ences relative to age, presenting condition, and educa-
tional level; this may be explained by the larger number
of participants and a better ability to detect statistical
differences. The positive influence of lower age and
higher education on knowledge has been confirmed by
other studies [11].
Research studies were considered useful by 91.6 % of
the patients, but only 52.8 % were actually willing to take
part in studies themselves. The discrepancy between gen-
eral approval of clinical studies and patients’ actual or real
willingness to take part in them has also been reported in
other studies [8, 13, 14]. Ellis et al. reported that women
who were willing to consider taking part in a randomized
trial were younger and had a higher educational level [8].
Both of these aspects were confirmed by the present
study, but there was also a group of very young women
who showed less willingness to participate.
A patient’s decision on whether to take part in a study
is influenced more by the potential disadvantages than
by the potential advantages [14]. The majority of the re-
spondents have a negative image of clinical studies and
of the potential disadvantages [14, 15]. Frequently men-
tioned reasons for not taking part in studies include, for
example, a fear of being used as a guinea-pig [8], the in-
creased personal effort involved [8, 16], and increased
personal risk [16]. Positive reasons for taking part in
studies that are mentioned often include making a
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contribution to scientific progress [13, 17], the hope that
one will receive what is currently the best form of treat-
ment [8] or better treatment and care in comparison
with the standard therapy [18], and benefits for future
generations [8, 13]. The present study shows that a total
of 37.1 % of the patients considered that future genera-
tions would be likely to benefit most from their partici-
pation in a study; by contrast, only 26.9 % thought that
they might benefit most as patients themselves.With re-
gard to external influencing factors, it has been shown
that recommendations by independent information ser-
vices often have a positive effect on willingness to par-
ticipate in studies [5, 8]. This effect was only moderate
in the present group, with only one in three patients be-
ing positively influenced by this.
Financial incentives only influenced around one in 10
patients in this group in their decision for or against tak-
ing part in studies. Reasons for the particularly positive
reaction to a financial bonus among women receiving
fertility treatment (21.9 %) are likely to be the high costs
of this form of treatment and the high level of the excess
charge for it that is not met by health insurance com-
panies. Younger patients were also more often influ-
enced by financial remuneration. This may be explained
by the general financial burdens faced by younger people
(e.g., relative to starting out on their careers, obtaining
mortgages for houses, and caring for children).
The great majority of the present group of patients
wanted to make the decision about whether or not to par-
ticipate in a study after consultation with the physician
treating them — but nevertheless independently. This find-
ing is also reflected in other studies [5, 15]. Women who
have an active decision-making style are more likely to take
part in studies than women with a passive decision-making
style [8]. Satisfaction with decision-making and subjective
informed consent is strongly associated with fewer regrets
about decisions [19].
The amount of information desired by patients is also
important in the context of autonomy when participat-
ing in a study. The majority of patients in the present
group (95.9 %) wanted to receive all of the available in-
formation during the consultation process. A similar pic-
ture has also been described in other studies [5, 15].
Patients who do not believe that they have fully under-
stood the implications of a study may ultimately feel re-
gret about their decision to participate [19].
Altruistic motivations generally play an important role
in study participation, as has often been shown in other
studies [20, 21]. In addition, the idea that there may be
benefits for future patients is associated with high levels
of knowledge [22]. Verheggen et al. found that altruistic
motives weakened the expected risks of study participa-
tion and led to the extra time involved being seen as less
burdensome, which in turn led to higher participation
rates [16]. In the present group, benefits for the partici-
pating patient were regarded as being only secondary;
this may be due to the supposed risks and disadvantages
of potential participation in a study. This attitude has
also been observed in other studies [14]. Although hav-
ing an altruistic attitude is positively associated with an
individual’s potential participation in research studies, it
is not a reliable predictive factor [8]. It is only when a
benefit for study participants themselves is seen that
study participation becomes probable [13, 23].
These findings — both from the current study and
also from the numerous other studies cited here — offer
some points of departure for optimizing study planning,
study design, patient recruitment, and also the conduct
of research studies and processing of the results. To
begin with, the way in which information is communi-
cated to patients should be optimized — e.g., through
early provision of information brochures, posters, etc., in
order to dispel incorrect ideas and thus reduce or pre-
vent anxieties [5, 10]. Presentations using audiovisual
media can have positive effects on the quality of infor-
mation and may increase willingness to participate, but
evidence on this is still weak and further research is ne-
cessary [24].
In addition, the personal relationship of trust between
the physician and the study participant, as well as the
availability of personal discussions, should be empha-
sized [25]. The specialist physician treating the patient
was the preferred contact person in the present group
(81.3 %) for providing information about a study. A sen-
sitive informed consent discussion strengthens the phys-
ician–patient relationship, and a positive relationship is
regarded as a predictive factor for participation in re-
search studies [26]. Training programs for physicians to
help develop special communication skills can lead to
more positive attitudes to clinical trials on the part of
patients [27].
Involvement of patients’ family physicians would
also be an important way of contacting patients in
connection with participation in research studies. It is
also important to estimate the financial and time pres-
sure involved for study participants and to provide
support when appropriate. This might take the form
of financial grants for travel costs or treatment costs,
for example [28].
The present study has limitations connected with the
composition of the study group, with a wide variety of
subgroups. There was also a wide range of responses for
each question with regard to the assessment of the pa-
tients’ level of knowledge about the design and conduct
of studies. One reason for this may have been the com-
prehensibility of some of the questions. There were no
defined subgroups that failed to respond to all of the
questions. A further limitation of the present study is
Lux et al. BMC Cancer  (2015) 15:587 Page 8 of 10
the reliability and validity of the instruments used. Al-
though the knowledge scale has been used in earlier
studies [5] and differences between results can be dis-
cussed on a reliable basis, the questionnaire itself was
designed for this study and validation is still lacking. On
the other hand, the comprehensibility of the question-
naire was checked using interviews with the first 20 par-
ticipants. Despite this, the overall group was very large,
compensating at least in part for the limitations men-
tioned. Another limitation is the fact that this study only
included female participants; however, other studies have
not identified any differences, or only minor differences,
between male and female participants [12, 22, 29].
Conclusions
This study shows that women with gynecological dis-
eases have only moderate knowledge about clinical stud-
ies. In addition, their knowledge and willingness to
participate in research studies are strongly dependent on
age (P < 0.001), educational level (P < 0.001), and pre-
senting condition (P < 0.001). Middle-aged patients,
those with a high educational level, and those who pre-
sented with pregnancy or endometriosis, were informed
best about research studies. A majority of the patients
considered that clinical studies were useful, but only a
few patients were also willing to take part in them. Vari-
ous factors may influence patients’ willingness to partici-
pate in medical studies and their attitudes toward the
design and conduct of such studies. General public in-
formation should be provided about the background to
research studies. To increase the rates of participation in
clinical studies, the patients need more intensive infor-
mation about the benefits to themselves that the relevant
study can offer. Physicians need to respond in a targeted
way to patients’ questions and anxieties. Future research
should concentrate on the development of tools (e.g.,
web-based tools) to optimize individualized information
provision about the background of research studies in
ways that are based on age, educational level, and health
condition. Tools of this sort and the effect of approval
for them from medical professional associations should
be evaluated in the framework of future clinical trials.
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